Time to SGLT2 inhibitors initiation in patients with heart failure

No abstract available.

Information

Citation

Moon J, Udell JA, Chong A, Fang J, Austin PC, Ko DT, Stukel TA, Atzema CL, Booth GL, Tu K, Naimark DMJ, Jackevicius CA. J Am Heart Assoc. 2024; Apr 2 [Epub ahead of print].

View Source

Contributing ICES Scientists

Discover More

Journal Article

16/03/2026

Hydralazine use and risk of vasculitis

Fremont D, Dhaliwal S, Canney M, Akbari A, Hundemer GL, Derebail VK, Sood MM, Massicotte-Azarniouch D. JAMA Netw Open. 2026; 9(3): e261943.

Journal Article

09/03/2026

Long-term risk of major coronary artery disease events after thrombotic microangiopathy treated with plasma exchange

Jamison HK, Bota SE, Garg AX, Kang Y, McArthur E, Huang SS, Clark WF, Sontrop JM, Eberhart AM. Am J Hematol. 2026; Mar 9 [Epub ahead of print].

Journal Article

09/03/2026

Risks of thrombosis and hemorrhage in concurrent use of anticoagulants and potential interacting prostate cancer agents

Wang TF, Clarke A, Rath M, Yoo S, Fremont D, Wu C, Ravani P, Bossé D, Talarico R, Carrier M, Sood MM. Cancer. 2026; 132(6):e70266.

See All

Time to SGLT2 inhibitors initiation in patients with heart failure

Information

Citation

Contributing ICES Scientists

Research Programs

Associated Topics

Associated Sites

Discover More

Hydralazine use and risk of vasculitis

Long-term risk of major coronary artery disease events after thrombotic microangiopathy treated with plasma exchange

Risks of thrombosis and hemorrhage in concurrent use of anticoagulants and potential interacting prostate cancer agents